Marshall Wace, LLP 89bio, Inc. Transaction History

Marshall Wace, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$6.66 - $16.03 $4.11 Million - $9.88 Million	-616,419 Reduced 52.65%	554,337 $6.19 Million
Q3 2023 Nov 14, 2023	SELL	$15.06 - $19.41 $13.8 Million - $17.8 Million	-915,286 Reduced 43.88%	1,170,756 $18.1 Million
Q2 2023 Aug 14, 2023	BUY	$14.15 - $22.03 $13.5 Million - $21.1 Million	956,571 Added 84.69%	2,086,042 $39.5 Million
Q1 2023 May 15, 2023	SELL	$10.48 - $16.94 $3.75 Million - $6.06 Million	-357,840 Reduced 24.06%	1,129,471 $17.2 Million
Q4 2022 Feb 14, 2023	BUY	$5.52 - $12.73 $5.73 Million - $13.2 Million	1,037,931 Added 230.97%	1,487,311 $18.9 Million
Q3 2022 Nov 14, 2022	BUY	$3.02 - $7.0 $905,510 - $2.1 Million	299,838 Added 200.5%	449,380 $2.6 Million
Q2 2022 Aug 15, 2022	BUY	$2.09 - $4.02 $312,542 - $601,158	149,542 New	149,542 $482,000
Q4 2020 Feb 16, 2021	SELL	$23.16 - $28.08 $768,101 - $931,273	-33,165 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$24.34 - $38.82 $807,236 - $1.29 Million	33,165 New	33,165 $851,000

158

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $415M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.